Incyte

$78.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (+0.27%) Today
+$0.01 (+0.01%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Incyte and other stocks, options, and ETFs commission-free!

About INCY

Incyte Corp. Common Stock, also called Incyte, is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. The listed name for INCY is Incyte Corp. Common Stock.

CEO
Herve Hoppenot
Employees
1,773
Headquarters
Wilmington, Delaware
Founded
1991
Market Cap
17.42B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.70M
High Today
$79.64
Low Today
$77.77
Open Price
$79.17
Volume
1.69M
52 Week High
$110.37
52 Week Low
$62.48

INCY News

MarketWatchFeb 26

Incyte Corp. stock rises Friday, outperforms market

Shares of Incyte Corp. INCY, +0.27% inched 0.27% higher to $78.66 Friday, on what proved to be an all-around poor trading session for the stock market, with the
ReutersFeb 23

Incyte must face Novartis contract claims in blood drug royalty fight

Delaware drug company Incyte Corp must face a lawsuit by Novartis Pharma AG accusing it of breaching a contract by reducing royalties it paid on a drug used to

INCY Earnings

-$2.86
-$1.49
-$0.13
$1.24
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 4, Pre-Market

You May Also Like

ISEE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure